Anemo Labs
Anemo Labs builds an electronic nose for non-invasive disease screening, using an olfactory chip with dozens of sensors and AI to detect volatile organic compounds in urine, sweat, and other bodily fluids. The company is initially focused on prostate cancer diagnostics, with a pre-clinical study protocol already approved. Their chip samples 48 channels in parallel, enabling early health signals before symptoms appear.
- Artificial Intelligence
- Biotechnology
- Drug Discovery & Therapeutics
- Hardware
- Healthcare Technology
- Medical Devices
Funding
Raised to date
£700KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Est. $889Kacross 1 round
IU£700K · Pre-Seed
Announced Sep 2026 · from article date
Disclosed cumulative: $889K
Founders
Founder details are not available yet.
Product
Problem
Nearly half of cancers are found too late, often only after symptoms appear, narrowing the window for early intervention. Current diagnostic methods are often invasive, expensive, or inaccessible, delaying detection and monitoring of progressive diseases.
Solution
Anemo Labs provides a non-invasive electronic nose for disease detection, designed to screen and monitor biomarkers in urine, sweat, and other bodily fluids. The technology uses an olfactory chip with dozens of parallel sensors to detect unique volatile organic compounds (VOCs), backed by AI models trained on extensive smell patterns. This approach aims to make biomarker monitoring cheap and accessible, enabling earlier health signals across multiple indicators. The company is initially applying its platform to prostate cancer diagnostics, with a pre-clinical study protocol already approved.
Target Audience
Primary customers are clinicians and diagnostic companies focused on cancer screening and monitoring, particularly in urology and oncology, as well as healthcare providers seeking non-invasive biomarker testing solutions.
Features
- Olfactory chip capable of sampling 48 channels in parallel for high-throughput VOC detection
- Proprietary polymer-based sensor array designed for selective binding of disease-specific volatile compounds
- In-house AI models trained on vast arrays of smell patterns to classify disease signatures
- Non-invasive sample analysis from urine, sweat, and other bodily fluids
- Pre-clinical study protocol approved for prostate cancer diagnostics
- Scalable synthetic polymer chemistry approach enabling rapid sensor iteration and production